Similarly, SRPK1 can control alternative splicing of MAP2K2 (a component of the MAPK pathway), where inhibition or knockdown of SRPK1 in pancreatic cancer cell lines led to increased sensitivity to chemotherapy agents [302]. The gene discussed is SRPK1; the disease is familial pancreatic carcinoma.